Antibody Engineering
With a deep understanding of antibody engineering, Alpha Lifetech can offer an excellent technical support and one-stop service.
Request QuoteWhat is Antibody Engineering?
Antibody engineering is a technology-driven approach that modifies and optimizes antibody structures to improve their functional properties, including binding affinity, specificity, stability, pharmacokinetics, immunogenicity, and effector functions. By introducing engineered antibody formats, such as bispecific and multispecific antibodies, antibody engineering enables the development of advanced antibody molecules with improved performance for research, diagnostic, and therapeutic applications.
Compared with naturally occurring antibodies, engineered antibodies can be customized to achieve enhanced characteristics for specific applications. Through technologies including gene cloning, recombinant expression, protein engineering, and structure-guided design, antibody engineering provides effective strategies for developing next-generation antibody therapeutics and diagnostic reagents.
Alpha Lifetech provides comprehensive antibody engineering services, supporting the development and optimization of monoclonal antibodies, polyclonal antibodies, and recombinant antibody products. Our integrated platforms cover antibody humanization, antibody sequencing, affinity optimization, antibody expression, purification, and functional validation. Combined with phage display and protein engineering technologies, we provide customized solutions throughout the antibody development pipeline.
The Development of Antibody Engineering
The advancement of antibody engineering has been driven by several key technologies:
Early-stage technologies:
Hybridoma technology for monoclonal antibody generation
Recombinant DNA technology for antibody gene manipulation and engineering
Modern antibody engineering technologies:
Gene cloning and PCR technology for antibody sequence isolation and modification Recombinant protein expression systems for antibody production and optimization Computer-aided structural design for rational antibody engineering and molecular optimization
Early-stage technologies:
Hybridoma technology for monoclonal antibody generation
Recombinant DNA technology for antibody gene manipulation and engineering
Modern antibody engineering technologies:
Gene cloning and PCR technology for antibody sequence isolation and modification Recombinant protein expression systems for antibody production and optimization Computer-aided structural design for rational antibody engineering and molecular optimization
Technologies Used in Antibody Engineering
Antibody engineering integrates multiple molecular biology and protein engineering technologies to modify antibody structures, improve functional properties, and develop next-generation antibody formats. Key technologies include hybridoma technology, antibody humanization, phage display, recombinant antibody technology, and cell-free expression systems.
Hybridoma Technology
One of the most common ways to produce monoclonal antibodies using hybridoma technology is by immunizing mice to produce B lymphocytes, which fuse with immortalized myeloma cells to generate hybridoma cell lines, and then screen for corresponding monoclonal antibodies against the corresponding antigens.
This technology remains widely used for producing high-specificity antibodies for research, diagnostic development, and therapeutic antibody discovery.
Antibody Humanization
Antibody humanization is an antibody engineering strategy designed to reduce immunogenicity while maintaining antigen-binding activity. Through technologies such as chimeric antibody construction and complementarity-determining region (CDR) grafting, non-human antibody sequences can be modified to generate antibody candidates with improved compatibility for human applications.
Humanized antibodies represent an important class of engineered antibodies widely used in therapeutic antibody development.
Fig 1: Chimeric Antibody Structure, Fig 2: Humanized Antibody Structure
Phage Display Technology
Phage display technology is a powerful antibody discovery platform that enables the screening and selection of antigen-specific antibodies from diverse antibody libraries. Antibody genes derived from immune, naïve, semi-synthetic, or synthetic libraries are cloned into phage display vectors and expressed on the surface of bacteriophages.
Through iterative selection and enrichment processes, antibodies with desired binding properties can be identified and further optimized. Phage display supports the discovery of various antibody formats, including scFv, Fab, and recombinant antibody fragments, providing an efficient approach for antibody engineering and optimization..
Fig 3: Antibody Library Construction and Screening
Recombinant Antibody Technology
Recombinant antibody technology enables the generation of engineered antibody fragments and optimized antibody formats through genetic manipulation and recombinant expression.
Common recombinant antibody formats include Fab fragments, Fv fragments, and single-chain variable fragments (scFv). By linking antibody variable regions through engineered peptide linkers, scFv antibodies can be generated with improved flexibility and convenient production characteristics.
Recombinant antibody technologies provide valuable tools for antibody engineering, molecular diagnostics, and therapeutic antibody development.
Fig 4: Fab Antibody and Fv Antibody Fragment
VHH / Nanobody Technology
VHH antibodies, also known as nanobodies or single-domain antibodies, are derived from camelid heavy-chain-only antibodies. With their small molecular size, high stability, and unique antigen recognition properties, VHH antibodies have become valuable platforms for antibody engineering and targeted applications.
Their compact structure enables improved tissue penetration and flexible engineering into various antibody formats.
Fig 5: Heavy Chain Antibody and VHH/ Nanobody
Cell-free Expression System
Cell-free expression systems enable rapid in vitro protein synthesis using DNA templates without the need for living cells. Compared with traditional expression platforms, cell-free systems offer advantages such as shorter production cycles, simplified optimization, and the ability to express proteins that may be difficult to produce using conventional cellular systems.
These systems provide an efficient platform for rapid antibody prototyping, protein engineering studies, and recombinant protein production.
01
/
Therapeutic Antibodies Development
Monoclonal Antibodies (mAbs) Production
Bispecific Antibodies Production
Antibody Drug Conjugation (ADC) Development
200
+
Project and Solution
02
/
Immunotherapy
Checkpoint Detection
CAR-T Cell Therapy
03
/
Vaccine Development
Recombinant Protein Vaccine Development
Viral Vector Vaccine Development
mRNA Vaccine Development
04
/
Targeted Drug Development
Biosimilar Antibody Development
800
+
Biosimilar Antibody Products
05 /
Neutralizing Antibodies Production
-----Neutralization Polyclonal Antibody Production
Neutralizing polyclonal antibodies have high affinity and can recognize multiple epitopes on antigens, thereby enhancing their binding ability to antigens and exhibiting high affinity. Neutralizing polyclonal antibodies have wide applications in biomedical research, such as protein function studies, cell signaling studies, and exploration of disease pathogenesis.
-----Neutralization Monoclonal Antibody Production
Neutralizing monoclonal antibodies directly neutralize viral particles, preventing the virus from entering cells and replicating, effectively inhibiting the spread and infection of the virus, and possessing high efficiency and efficacy. Neutralizing monoclonal antibodies are commonly used for studying viral epitopes and the interaction between viruses and host cells, providing a theoretical basis for virus prevention, control, and treatment.
